Edinburgh Research Explorer

Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance

Research output: Contribution to journalArticle

  • Catarina Sepulveda
  • Theano I Panagopoulou
  • Juan Menendez-Gonzalez
  • Juan Manuel Iglesias
  • Lewis Allen
  • Fokion Glykofrydis
  • Alejandro Armesilla-Diaz
  • Annemarie E M Post
  • Deniz Gezer
  • Chi Wai Eric So
  • Tessa L Holyoake
  • Peter J Ratcliffe

Related Edinburgh Organisations

Open Access permissions



  • Download as Adobe PDF

    Rights statement: RUP copyright policy: http://www.rupress.org/site/subscriptions/terms.xhtml

    Final published version, 1.85 MB, PDF document

    Licence: Unspecified

Original languageEnglish
Pages (from-to)2223-2234
Number of pages12
JournalJournal of Experimental Medicine
Issue number13
Publication statusPublished - 14 Dec 2015


Leukemogenesis occurs under hypoxic conditions within the bone marrow (BM). Knockdown of key mediators of cellular responses to hypoxia with shRNA, namely hypoxia-inducible factor-1α (HIF-1α) or HIF-2α, in human acute myeloid leukemia (AML) samples results in their apoptosis and inability to engraft, implicating HIF-1α or HIF-2α as therapeutic targets. However, genetic deletion of Hif-1α has no effect on mouse AML maintenance and may accelerate disease development. Here, we report the impact of conditional genetic deletion of Hif-2α or both Hif-1α and Hif-2α at different stages of leukemogenesis in mice. Deletion of Hif-2α accelerates development of leukemic stem cells (LSCs) and shortens AML latency initiated by Mll-AF9 and its downstream effectors Meis1 and Hoxa9. Notably, the accelerated initiation of AML caused by Hif-2α deletion is further potentiated by Hif-1α codeletion. However, established LSCs lacking Hif-2α or both Hif-1α and Hif-2α propagate AML with the same latency as wild-type LSCs. Furthermore, pharmacological inhibition of the HIF pathway or HIF-2α knockout using the lentiviral CRISPR-Cas9 system in human established leukemic cells with MLL-AF9 translocation have no impact on their functions. We therefore conclude that although Hif-1α and Hif-2α synergize to suppress the development of AML, they are not required for LSC maintenance.

    Research areas

  • Animals, Base Sequence, Basic Helix-Loop-Helix Transcription Factors, CRISPR-Cas Systems, Cell Hypoxia, Cell Line, Tumor, Cell Proliferation, Cell Survival, Disease Models, Animal, Disease Progression, Gene Deletion, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Homeodomain Proteins, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Leukemia, Myeloid, Acute, Mice, Molecular Sequence Data, Neoplasm Proteins, Neoplastic Stem Cells

Download statistics

No data available

ID: 21882809